Organon & Co. Common Stock vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Organon & Co. Common Stock trades at $13.77 (market cap $3.61B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $70.18 (market cap $7.74B). The key difference: Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is far larger — about 2.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 4 Days on average.
| OGN | VIST | |
|---|---|---|
Market Cap | $3.61B | $7.74B |
Volume | 1,808,049 | 797,145 |
Sector | Health | Energy |
52-Week High | $13.81 | $79.25 |
52-Week Low | $5.70 | $35.02 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $11.03B | $10.88B |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Vista Energy (VIST) trades at $69.02, down 0.58% on the day, with strong bullish technical signals from moving averages despite recent earnings misses. The company demonstrates robust fundamentals with 52.72% gross margins and 23.88% net income margins, supported by 32% production growth in Q2 2026. Recent news highlights Peter Thiel's $418 million investment and positive coverage from Seeking Alpha citing 70% EBITDA margins.
The outlook remains positive with 100% analyst buy ratings and $91 consensus price target representing 32% upside. Key risks include consecutive earnings misses, high debt levels, and oil price volatility. The stock offers attractive valuation at 9.08 P/E with strong operational momentum in Argentina's Vaca Muerta basin driving growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →